Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | LATS1 | O95835 | 1/20 | 0.34 |
| ▸ | LATS2 | Q9NRM7 | 1/20 | 0.34 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.34 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.33 |
| ▸ | LPL | P06858 | 3/20 | 0.32 |
| ▸ | LIPG | Q9Y5X9 | 3/20 | 0.32 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.31 |
| ▸ | CDK9 | P50750 | 1/20 | 0.31 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.31 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29572040 | 1.00 | HTT (0.37) | HTTKMT2AMEN1LATS1LATS2 | |
| SCHEMBL9936199 | 0.90 | HTT (0.37) | HTTKMT2AMEN1LATS1LATS2 | |
| SCHEMBL29768444 | 0.90 | HTT (0.37) | HTTKMT2AMEN1LATS1LATS2 | |
| SCHEMBL2187689 | 0.80 | LATS1 (0.35) | HTTKMT2AMEN1LATS1LATS2 | |
| SCHEMBL27191758 | 0.78 | ESR2 (0.31) | ESR2 | |
| SCHEMBL31663361 | 0.78 | ESR2 (0.31) | ESR2 | |
| SCHEMBL29515710 | 0.77 | LPL (0.34) | LPLLIPGCYP2E1CYP2C8CYP2D6 | |
| SCHEMBL2352761 | 0.77 | LPL (0.34) | LPLLIPGCYP2E1CYP2C8CYP2D6 | |
| SCHEMBL520252 | 0.77 | LPL (0.42) | HTTESR2LPLLIPGALDH1A1 | |
| SCHEMBL30107439 | 0.77 | LPL (0.40) | LPLLIPGCYP2E1CYP2C8CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12466815-B2 | Carboxamide compounds and uses thereof | INCYTE CORPORATION (US) | 2025-11-11 | — | — | US | disclosed |
| US-12410183-B2 | Sars-cov2 main protease inhibitors | GILEAD SCIENCES, INC. (US) | 2025-09-09 | — | — | US | disclosed |
| EP-4594318-A1 | AKT1 MODULATORS | Alterome Therapeutics, Inc. (US) | 2025-08-06 | — | — | EP | disclosed |
| EP-4069697-B1 | CRF RECEPTOR ANTAGONISTS AND METHODS OF USE | NEUROCRINE BIOSCIENCES INC (US) | 2025-07-16 | — | — | EP | disclosed |
| WO-2025092989-A1 | SUBSTITUTED QUINAZOLINE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMBINATION THEREOF, AND USE THEREOF | 泰州红云制药有限公司 | 2025-05-08 | — | — | WO | disclosed |
| US-20250122174-A1 | Heteroaryl Compounds As HPK1 Inhibitors And Methods Of Using Same | SHENZHEN YUANLI SHENWAN INNOVATIVE MEDICINE CO LTD (CN) | 2025-04-17 | — | — | US | disclosed |
| US-20250092040-A1 | AKT1 MODULATORS | ALTEROME THERAPEUTICS, INC. | 2025-03-20 | — | — | US | disclosed |
| US-20250042915-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | GILEAD SCIENCES, INC. | 2025-02-06 | — | — | US | disclosed |
| EP-4463150-A1 | HETEROARYL COMPOUNDS AS HPK1 INHIBITORS AND METHODS OF USING SAME | Shenzhen Ionova Life Science Co., Ltd. (CN) | 2024-11-20 | — | — | EP | disclosed |
| US-20240368170-A1 | CINNOLINE COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2024-11-07 | — | — | US | disclosed |
| US-8765784-B2 | Positive allosteric modulators of MGLUR2 | MERCK SHARP & DOHME CORP. (US) | 2014-07-01 | — | — | US | disclosed |
| US-8765784-B2 | Positive allosteric modulators of MGLUR2 | MERCK SHARP & DOHME CORP. (US) | 2014-07-01 | — | — | US | disclosed |
| US-20130210768-A1 | POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 | MERCK SHARP & DOHME LLC | 2013-08-15 | — | — | US | disclosed |
| US-20130210768-A1 | POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 | MERCK SHARP & DOHME LLC | 2013-08-15 | — | — | US | disclosed |
| WO-2011156245-A2 | POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 | MERCK SHARP & DOHME CORP. (US) | 2011-12-15 | — | — | WO | disclosed |
| US-20090233943-A9 | NEW COMPOUNDS 835 | ASTEX THERAPEUTICS LIMITED (GB) | 2009-09-17 | — | — | US | disclosed |
| WO-2008150217-A1 | 2-AMINO-5, 5-DIARYL-IMIDAZOL-4-ONE ANALOGS FOR THE INHIBITION OF BETA-SECRETASE | ASTRAZENECA AB (SE) | 2008-12-11 | — | — | WO | disclosed |
| US-20080287460-A1 | NEW COMPOUNDS 835 | ASTEX THERAPEUTICS LIMITED (GB) | 2008-11-20 | — | — | US | disclosed |
| US-20080161269-A1 | Compounds 620 | ASTRAZENECA AB (SE) | 2008-07-03 | — | — | US | disclosed |
| WO-2008076045-A1 | NOVEL 2-AMINO- 5-ARYL-IMIDAZOL-4 -ONES | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161269-A1 | Compounds 620 | MAPT, PSEN1, PSEN2 | HTT 32/4885KMT2A 3211/4885MEN1 3173/4885 |
| US-20080287460-A1 | NEW COMPOUNDS 835 | GRIK5, MAPT, PSEN1 | HTT 41/4885KMT2A 2568/4885MEN1 2937/4885 |
| US-20250042915-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | ACE2, TMPRSS2, ACE | HTT 3577/4885KMT2A 3085/4885MEN1 3914/4885 |
| US-20240368170-A1 | CINNOLINE COMPOUNDS AND USES THEREOF | HIPK1, CDC7, MAP3K7 | HTT 2964/4885KMT2A 2199/4885MEN1 313/4885 |
| US-20130210768-A1 | POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 | GRM2, GRM1, GRIA2 | HTT 583/4885KMT2A 982/4885MEN1 4803/4885 |
| US-12410183-B2 | Sars-cov2 main protease inhibitors | ACE2, TMPRSS2, ACE | HTT 3577/4885KMT2A 3085/4885MEN1 3914/4885 |
| US-20250122174-A1 | Heteroaryl Compounds As HPK1 Inhibitors And Methods Of Using Same | SGK1, HYPK, PCK1 | HTT 1241/4885KMT2A 2422/4885MEN1 2249/4885 |
| US-20090233943-A9 | NEW COMPOUNDS 835 | GRIK5, MAPT, PSEN1 | HTT 41/4885KMT2A 2568/4885MEN1 2937/4885 |
| US-20250092040-A1 | AKT1 MODULATORS | AKT1S1, AKT1, AKT2 | HTT 860/4885KMT2A 1301/4885MEN1 1284/4885 |
| US-12466815-B2 | Carboxamide compounds and uses thereof | PCK1, PHKG2, PHKG1 | HTT 2370/4885KMT2A 1609/4885MEN1 2274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.